Abstract
The UroVysion fluorescence in situ hybridization assay[FISH][Vysis Inc, Illinois, USA] is a multi-target assay that detects aneuploidy of chromosomes 3, 7 and 17 and loss of the 9p21 band in exfoliated cells in urine from patients with transitional cell carcinoma[TCC]. The nuclear matrix protein 22[NMP22] detects elevated amounts of nuclear mitotic apparatus protein, a component of the nuclear matrix essential for cell division that is released into urine at cell death. Both tests have been reported to have higher sensitivity and specificity than urine cytology in patients with cystoscopic and histologic TCC either at initial diagnosis or recurrence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
